Mechanisms of Uropathogenic Escherichia coli Persistence and Eradication from the Urinary Tract

Recurrent urinary tract infections (rUTIs) are a source of considerable morbidity in women. The infecting bacteria in both rUTIs and a de novo acute infection have been thought to originate from an extraurinary location. Here, we show in a murine model of UTI that uropathogenic Escherichia coli (UPE...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 103; no. 38; pp. 14170 - 14175
Main Authors Mysorekar, Indira U., Hultgren, Scott J.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 19.09.2006
National Acad Sciences
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Recurrent urinary tract infections (rUTIs) are a source of considerable morbidity in women. The infecting bacteria in both rUTIs and a de novo acute infection have been thought to originate from an extraurinary location. Here, we show in a murine model of UTI that uropathogenic Escherichia coli (UPEC) established quiescent intracellular reservoirs (QIRs) in Lamp1⁺ endosomes within the urinary bladder epithelium. Depending on the integrity of the urothelial barriers at the time of initial infection, these QIRs were established within terminally differentiated superficial facet cells and/or underlying transitional epithelial cells. Treatment of infected bladders harboring exclusively superficial facet cell QIRs with the cationic protein, protamine sulfate, led to epithelial exfoliation and eradication of bacteria in 100% of treated animals. However, when the bacterial QIRs were harbored in underlying transitional cells, stimulation of epithelial turnover triggered reemergence of viable organisms and recurrence of infection. Thus, our results suggest (i) that bacterial QIRs within the bladder may be a previously unappreciated source of recurrent UTIs and (ii) that inducing epithelial exfoliation may be a therapeutic avenue for treating this heretofore recalcitrant disease.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
Edited by Jeffrey Gordon, Washington University School of Medicine, St. Louis, MO, and approved July 31, 2006
Author contributions: I.U.M. and S.J.H. designed research; I.U.M. performed research; I.U.M. analyzed data; and I.U.M. and S.J.H. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.0602136103